| A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy (NCT07582133) | Chengdu Suncadia Medicine Co., Ltd. | 2026-07-06 |
| A Clinical Study of HRS-8797 in Healthy Participants (NCT07698756) | Chengdu Suncadia Medicine Co., Ltd. | 2026-07-01 |
| Phase I Study of HRS-1635 in B-cell Malignancies (NCT07583212) | Chengdu Suncadia Medicine Co., Ltd. | 2026-06-30 |
| A Clinical Study of HRS-5765 in Healthy Participants (NCT07551167) | Chengdu Suncadia Medicine Co., Ltd. | 2026-05-20 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Doses of HRS-3095 Oral Administration in Healthy Subjects, as Well as the Effect of HRS-3095 on CYP3A4 Metabolic Enzymes (NCT07230418) | Chengdu Suncadia Medicine Co., Ltd. | 2025-11-10 |
| Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects (NCT07040787) | Chengdu Suncadia Medicine Co., Ltd. | 2025-07-08 |
| A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects (NCT07035665) | Chengdu Suncadia Medicine Co., Ltd. | 2025-06-30 |
| A Trial of HRS-5965 Capsule in Primary IgA Nephropathy (NCT07014826) | Chengdu Suncadia Medicine Co., Ltd. | 2025-06-04 |
| Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody Treatment (NCT06715943) | Chengdu Suncadia Medicine Co., Ltd. | 2025-01-07 |
| A Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Study, and QT Interval Study of HRS-5965 Capsules in Healthy Subjects (NCT06684041) | Chengdu Suncadia Medicine Co., Ltd. | 2024-11-09 |
| A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy (NCT06593938) | Chengdu Suncadia Medicine Co., Ltd. | 2024-10-25 |
| A Study to Evaluate the Mass Balance of [14C] HRS-5965 in Healthy Adult Male Volunteers (NCT06567392) | Chengdu Suncadia Medicine Co., Ltd. | 2024-09-03 |
| Comparison of HRS-5965 Capsules and Tablets in Healthy Subjects (NCT06490991) | Chengdu Suncadia Medicine Co., Ltd. | 2024-07-17 |
| Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria (NCT06238544) | Chengdu Suncadia Medicine Co., Ltd. | 2024-02-06 |
| A Trial of HRS-5965 Tablets in Primary IgA Nephropathy (NCT06137768) | Chengdu Suncadia Medicine Co., Ltd. | 2023-12-19 |
| Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria (NCT06051357) | Chengdu Suncadia Medicine Co., Ltd. | 2023-11-15 |
| A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs) (NCT05905458) | Chengdu Suncadia Medicine Co., Ltd. | 2023-07-28 |
| Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency (NCT05505955) | Chengdu Suncadia Medicine Co., Ltd. | 2022-10-08 |
| A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism (NCT04994080) | Chengdu Suncadia Medicine Co., Ltd. | 2022-02-01 |